NAF is gathering feedback from the Ataxia community to submit to the FDA and we need your input! We’re concerned with the FDA’s decision to refuse to file Biohaven’s new drug application (NDA) for troriluzole without a full review of the clinical trial results
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Breaking news re Troriluzole..the FDA has granted Priority Review | 0 | 50 | February 11, 2025 | |
| NAF Webinar…to discuss progress re TRORILUZOLE | 0 | 33 | November 18, 2024 | |
| Reminder Dec 10 2024…Webinair..All about Troriluzole presented by Dr Susan Perlman | 0 | 33 | December 5, 2024 | |
| Troriluzole..optimism re SCA3 | 0 | 164 | May 24, 2022 | |
| I received that E-mail from NAF | 18 | 745 | December 18, 2019 |